Advertisement for orthosearch.org.uk
Results 1 - 20 of 41
Results per page:
Bone & Joint Research
Vol. 11, Issue 6 | Pages 342 - 345
1 Jun 2022
Hall AJ Clement ND MacLullich AMJ Simpson AHRW White TO Duckworth AD

Research into COVID-19 has been rapid in response to the dynamic global situation, which has resulted in heterogeneity of methodology and the communication of information. Adherence to reporting standards would improve the quality of evidence presented in future studies, and may ensure that findings could be interpreted in the context of the wider literature. The COVID-19 pandemic remains a dynamic situation, requiring continued assessment of the disease incidence and monitoring for the emergence of viral variants and their transmissibility, virulence, and susceptibility to vaccine-induced immunity. More work is needed to assess the long-term impact of COVID-19 infection on patients who sustain a hip fracture. The International Multicentre Project Auditing COVID-19 in Trauma & Orthopaedics (IMPACT) formed the largest multicentre collaborative audit conducted in orthopaedics in order to provide an emergency response to a global pandemic, but this was in the context of many vital established audit services being disrupted at an early stage, and it is crucial that these resources are protected during future health crises. Rapid data-sharing between regions should be developed, with wider adoption of the revised 2022 Fragility Fracture Network Minimum Common Data Set for Hip Fracture Audit, and a pragmatic approach to information governance processes in order to facilitate cooperation and meta-audit. This editorial aims to: 1) identify issues related to COVID-19 that require further research; 2) suggest reporting standards for studies of COVID-19 and other communicable diseases; 3) consider the requirement of new risk scores for hip fracture patients; and 4) present the lessons learned from IMPACT in order to inform future collaborative studies. Cite this article: Bone Joint Res 2022;11(6):342–345


Bone & Joint Research
Vol. 12, Issue 4 | Pages 256 - 258
3 Apr 2023
Farrow L Evans J

Cite this article: Bone Joint Res 2023;12(4):256–258.


Bone & Joint Research
Vol. 12, Issue 10 | Pages 654 - 656
16 Oct 2023
Makaram NS Simpson AHRW

Cite this article: Bone Joint Res 2023;12(10):654–656.


The Bone & Joint Journal
Vol. 106-B, Issue 4 | Pages 303 - 306
1 Apr 2024
Staats K Kayani B Haddad FS


Bone & Joint Research
Vol. 12, Issue 3 | Pages 199 - 201
7 Mar 2023
Brzeszczyńska J Brzeszczyński F

Cite this article: Bone Joint Res 2023;12(3):199–201.


Bone & Joint 360
Vol. 13, Issue 2 | Pages 5 - 6
1 Apr 2024
Ollivere B


Bone & Joint Research
Vol. 12, Issue 8 | Pages 494 - 496
9 Aug 2023
Clement ND Simpson AHRW

Cite this article: Bone Joint Res 2023;12(8):494–496.


Bone & Joint Research
Vol. 11, Issue 8 | Pages 514 - 517
10 Aug 2022
Little CB Zaki S Blaker CL Clarke EC

Cite this article: Bone Joint Res 2022;11(8):514–517.


Bone & Joint Research
Vol. 11, Issue 4 | Pages 210 - 213
1 Apr 2022
Fontalis A Haddad FS


Bone & Joint Research
Vol. 11, Issue 1 | Pages 29 - 31
20 Jan 2022
Ma M Tan Z Li W Zhang H Liu Y Yue C


Bone & Joint Research
Vol. 11, Issue 1 | Pages 26 - 28
20 Jan 2022
Ma M Tan Z Li W Zhang H Liu Y Yue C


Bone & Joint Research
Vol. 11, Issue 1 | Pages 23 - 25
17 Jan 2022
Matar HE Platt SR Bloch BV Board TN Porter ML Cameron HU James PJ


Bone & Joint Research
Vol. 10, Issue 12 | Pages 840 - 843
15 Dec 2021
Al-Hourani K Tsang SJ Simpson AHRW


Bone & Joint Research
Vol. 10, Issue 10 | Pages 690 - 692
1 Oct 2021
Hoellwarth JS Tetsworth K Akhtar MA Al Muderis M


Bone & Joint Research
Vol. 10, Issue 6 | Pages 348 - 350
1 Jun 2021
Skinner JA Sabah SA Hart AJ


Bone & Joint Research
Vol. 10, Issue 2 | Pages 134 - 136
1 Feb 2021
Im G

The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods.

Cite this article: Bone Joint Res 2021;10(2):134–136.


Bone & Joint Open
Vol. 2, Issue 1 | Pages 1 - 2
1 Jan 2021
Haddad FS


Bone & Joint Open
Vol. 1, Issue 12 | Pages 749 - 750
7 Dec 2020
Haddad FS


Bone & Joint Research
Vol. 9, Issue 6 | Pages 279 - 281
1 Jun 2020
Clement ND Deehan DJ


Bone & Joint Research
Vol. 8, Issue 6 | Pages 224 - 225
1 Jun 2019
Wilkinson JM